Connect Biopharma Hldgs (CNTB) closed at $0.64 on November 16, 2026, down 5.0% from the previous close, on volume of 419,582 shares (30-day average 848,215).
Data as of November 16, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 16, 2026. See the largest for 5, 30, 60 and 90 days
TipRanks (Tue, 17-Nov 11:10 AM ET)
Connect Biopharma Holdings (CNTB) Gets a Buy from Leerink Partners
TipRanks (Tue, 17-Nov 8:16 AM ET)
TipRanks (Tue, 17-Nov 8:10 AM ET)
Seeking Alpha News (Tue, 17-Nov 3:42 AM ET)
Connect Biopharma Receives Nasdaq Minimum Bid Price Compliance Notice
TipRanks (Mon, 16-Nov 5:13 PM ET)
Connect Biopharma Reports Third Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Mon, 16-Nov 4:05 PM ET)
3 Biotech Stocks Throwing Their Weight Around, and Another that Wants to Help You Lose Yours
Globe Newswire (Wed, 30-Sep 10:22 AM ET)
CNTB jumps after Phase 2 COPD trial reports 100% reduction in return ED/hospital visits at one month
Market Chameleon (Wed, 30-Sep 5:51 AM ET)
Globe Newswire (Wed, 30-Sep 7:00 AM ET)
Market Chameleon (Wed, 16-Sep 7:05 AM ET)
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
Connect Biopharma Hldgs trades on the NASDAQ stock market under the symbol CNTB.
As of November 17, 2026, CNTB stock price declined to $0.61 with 638,475 million shares trading.
CNTB has a beta of -1.16, meaning it tends to be less sensitive to market movements. CNTB has a correlation of 0.02 to the broad based SPY ETF.
CNTB has a market cap of $38.41 million. This is considered a Sub-Micro Cap stock.
Last quarter Connect Biopharma Hldgs reported $736,000 in Revenue and -$.26 earnings per share. This fell short of revenue expectation by $-4 million and met earnings estimates .
In the last 3 years, CNTB traded as high as $3.82 and as low as $.51.
The top ETF exchange traded funds that CNTB belongs to (by Net Assets): IWM, VTWO, IWO, IWN, IWC.
CNTB has underperformed the market in the last year with a price return of -71.2% while the SPY ETF gained +10.0%. CNTB has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -76.1% and -21.5%, respectively, while the SPY returned -5.6% and -2.8%, respectively.
CNTB support price is $.61 and resistance is $.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CNTB shares will trade within this expected range on the day.